{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:27Z","timestamp":1788848427989,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370225"],"award-info":[{"award-number":["82370225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical and Translational Research Project of Anhui Province","award":["202427b10020064"],"award-info":[{"award-number":["202427b10020064"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epstein-Barr virus (EBV) is an oncovirus belonging to the herpesvirus family, associated with the pathogenesis of multiple malignancies, particularly Burkitt lymphoma (BL). The virus remains latent in host cells and plays a critical role in tumor progression through various mechanisms. A key glycoprotein, gp350, expressed during the lytic phase of EBV, is instrumental in viral entry into B cells and presents a unique antigenic target, making it a promising candidate for immunotherapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we engineered CAR-T cells targeted against the gp350 glycoprotein and assessed their therapeutic potential through a series of in vitro and in vivo experiments. The efficacy of the gp350-CAR-T cells was evaluated by comparing their cytotoxic effects against both EBV-positive and -negative tumor cell lines. We utilized a xenograft model of Burkitt lymphoma to monitor the impact of gp350-CAR-T cell administration on tumor progression and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The engineered gp350-CAR-T cells demonstrated potent cytotoxicity specifically against EBV-positive tumor cell lines. In our in vivo xenograft model, administration of gp350-CAR-T cells resulted in significant inhibition of tumor growth, highlighting their capability to effectively target and eliminate EBV-positive lymphomas. This selectivity underscores the potential of utilizing gp350 as a specific target for immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings advocate for the clinical application of gp350-directed CAR-T therapy as a prospective treatment strategy for patients with relapsed or refractory EBV-positive tumors. Given the encouraging preclinical results, further research is warranted to optimize CAR-T cell production processes and extend the potential of this therapy to other EBV-associated malignancies, paving the way for improved outcomes in affected patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-06188-w","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:52:12Z","timestamp":1739166732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T"],"prefix":"10.1186","volume":"23","author":[{"given":"Jiajia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengneng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengya","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tielin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4253-9322","authenticated-orcid":false,"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"20","key":"6188_CR1","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-barr virus: biology and clinical disease. Cell. 2022;185(20):3652\u201370.","journal-title":"Cell"},{"issue":"13","key":"6188_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJM198109243051305","volume":"305","author":"JL Ziegler","year":"1981","unstructured":"Ziegler JL. Burkitt s lymphoma. N Engl J Med. 1981;305(13):735\u201345.","journal-title":"N Engl J Med"},{"issue":"1","key":"6188_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C Lopez","year":"2022","unstructured":"Lopez C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, Orem J, Rochford R, Roschewski M, Siebert R. Burkitt lymphoma. Nat Rev Dis Prim. 2022;8(1):78.","journal-title":"Nat Rev Dis Prim"},{"issue":"7","key":"6188_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood.2019000568","volume":"134","author":"PG Murray","year":"2019","unstructured":"Murray PG, Young LS. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood. 2019;134(7):591\u20136.","journal-title":"Blood"},{"issue":"3","key":"6188_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/his.14585","volume":"80","author":"H Liu","year":"2022","unstructured":"Liu H, Xu-Monette ZY, Tang G, Wang W, Kim Y, Yuan J, Li Y, Chen W, Li Y, Fedoriw GY, et al. EBV(+) high-grade B cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022;80(3):575\u201388.","journal-title":"Histopathology"},{"issue":"7971","key":"6188_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"8","key":"6188_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000907","volume":"7","author":"V Bucklein","year":"2023","unstructured":"Bucklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, et al. Inferior OUTCOMES of EU versus US patients treated With CD19 CAR-T for relapsed\/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use. Hemasphere. 2023;7(8): e907.","journal-title":"Hemasphere"},{"key":"6188_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13: 927153.","journal-title":"Front Immunol"},{"issue":"11","key":"6188_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nsmb1161","volume":"13","author":"G Szakonyi","year":"2006","unstructured":"Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol. 2006;13(11):996\u20131001.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"6188_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","volume":"50","author":"JWJ Tanner","year":"1987","unstructured":"Tanner JWJ, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50(2):203\u201313.","journal-title":"Cell"},{"issue":"3","key":"6188_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/JVI.02531-15","volume":"90","author":"M Herrman","year":"2016","unstructured":"Herrman M, Muhe J, Quink C, Wang F. Epstein-Barr virus gp350 can functionally replace the rhesus lymphocryptovirus major membrane glycoprotein and does not restrict infection of rhesus macaques. J Virol. 2016;90(3):1222\u201330.","journal-title":"J Virol"},{"issue":"22","key":"6188_CR12","doi-asserted-by":"publisher","first-page":"11217","DOI":"10.1128\/JVI.01673-08","volume":"82","author":"KA Young","year":"2008","unstructured":"Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2\/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol. 2008;82(22):11217\u201327.","journal-title":"J Virol"},{"issue":"3","key":"6188_CR13","first-page":"462","volume":"17","author":"H Xiu","year":"2022","unstructured":"Xiu H, Nan X, Guo D, Wang J, Li J, Peng Y, Xiong G, Wang S, Wang C, Zhang G, et al. Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies. Asian J Pharm Sci. 2022;17(3):462\u201374.","journal-title":"Asian J Pharm Sci"},{"key":"6188_CR14","doi-asserted-by":"publisher","first-page":"1103695","DOI":"10.3389\/fimmu.2023.1103695","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang T, Zhu X, Lu Y, Li M, Huang Z, Han D, Zhang L, Wu Y, Li L, et al. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Front Immunol. 2023;14:1103695.","journal-title":"Front Immunol"},{"key":"6188_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","volume":"18","author":"C Slabik","year":"2020","unstructured":"Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, Kronke N, Feuerhake F, Ferreira de Figueiredo C, Blasczyk R, et al. CAR-T cells targeting epstein-barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncol. 2020;18:504\u201324.","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"6188_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569\u201375.","journal-title":"Nat Med"},{"issue":"9967","key":"6188_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet"},{"key":"6188_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126\u201333.","journal-title":"Cancer Lett"},{"issue":"2","key":"6188_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"6188_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6188_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, Chauhan R, Dagar M, Mirza S, Bagga P, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21(1):449.","journal-title":"J Transl Med"},{"issue":"7","key":"6188_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s00120-021-01569-7","volume":"60","author":"IM Zraik","year":"2021","unstructured":"Zraik IM, Hess-Busch Y. Management of chemotherapy side effects and their long-term sequelae. Urologe A. 2021;60(7):862\u201371.","journal-title":"Urologe A"},{"issue":"4","key":"6188_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s00120-017-0338-z","volume":"56","author":"K Hauner","year":"2017","unstructured":"Hauner K, Maisch P, Retz M. Side effects of chemotherapy. Urologe A. 2017;56(4):472\u20139.","journal-title":"Urologe A"},{"issue":"3","key":"6188_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","volume":"1","author":"R Thibaut","year":"2020","unstructured":"Thibaut R, Bost P, Milo I, Cazaux M, Lemaitre F, Garcia Z, Amit I, Breart B, Cornuot C, Schwikowski B, et al. Bystander IFN-gamma activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat Cancer. 2020;1(3):302\u201314.","journal-title":"Nat Cancer"},{"issue":"3","key":"6188_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","volume":"25","author":"F Balkwill","year":"2006","unstructured":"Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409\u201316.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"6188_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215\u201328.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"6188_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/hon.3153","volume":"41","author":"AP Boardman","year":"2023","unstructured":"Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. Hematol Oncol. 2023;41(Suppl 1):112\u20138.","journal-title":"Hematol Oncol"},{"issue":"3","key":"6188_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"JBE Gauthier","year":"2021","unstructured":"Gauthier JBE, Hirayama AV, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137(3):323\u201335.","journal-title":"Blood"},{"issue":"3","key":"6188_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transpl. 2021;56(3):552\u201366.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6188_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","volume":"4","author":"AL Garfall","year":"2023","unstructured":"Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, et al. Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 2023;4(2):118\u201333.","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"6188_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"1","key":"6188_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","volume":"8","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C, Wang D, Shi Z, Yan X, Li X, et al. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Signal Transduct Target Ther. 2023;8(1):457.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"6188_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"6188_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69.","journal-title":"Exp Hematol Oncol"},{"key":"6188_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914780","author":"MA Perez-Moreno","year":"2023","unstructured":"Perez-Moreno MA, Ciudad-Gutierrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Martin L, Flores-Moreno S. Combined or sequential treatment with immune checkpoint inhibitors and Car-T cell therapies for the management of haematological malignancies: a systematic review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241914780.","journal-title":"Int J Mol Sci"},{"key":"6188_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122387","volume":"338","author":"S Najafi","year":"2024","unstructured":"Najafi S, Mortezaee K. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: a focus on anti PD-1\/PD-L1 antibodies. Life Sci. 2024;338: 122387.","journal-title":"Life Sci"},{"issue":"1","key":"6188_CR37","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, Muhlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsague J, Braso-Maristany F, Calderon H, Angelats L, Colell S, et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024;15(1):3552.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06188-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:52:17Z","timestamp":1739166737000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06188-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6188"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06188-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the 1975 Declaration of Helsinki and was approved by the Medical Research Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Approval No. YJ-YX2019-015). Written informed consent was obtained from all participants, ensuring full protection of their privacy and anonymity throughout the study. Animal experiments in this study were also approved by the same ethics committee (Approval No. YJ-YX2019-015) and conducted in accordance with the International Guiding Principles for Biomedical Research Involving Animals. All animal housing and experiments strictly followed the guidelines for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}